STAAR Surgical Company  

(Public, NASDAQ:STAA)   Watch this stock  
Find more results for STAA
8.64
+0.04 (0.47%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.51 - 8.69
52 week 4.96 - 10.26
Open 8.60
Vol / Avg. 170,605.00/201,558.00
Mkt cap 317.49M
P/E     -
Div/yield     -
EPS -0.04
Shares 36.75M
Beta 1.20
Inst. own 77%
Jul 31, 2013
Q2 2013 Staar Surgical Co Earnings Release Add to calendar
May 13, 2013
Staar Surgical Co Annual Stockholder Meeting
May 1, 2013
Q1 2013 Staar Surgical Co Earnings Conference Call - Webcast
May 1, 2013
Q1 2013 Staar Surgical Co Earnings Release
Apr 20, 2013
ASCRS Symposium on Cataract and Refractive Surgery - Investor Briefing - Webcast
Feb 27, 2013
Q4 2012 Staar Surgical Co Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 2.62% -2.76%
Operating margin 6.02% -1.91%
EBITD margin - 1.16%
Return on average assets 3.52% -3.40%
Return on average equity 5.87% -5.76%
Employees 301 -
Carbon Disclosure Rating - -

Address

1911 Walker Ave
MONROVIA, CA 91016
United States - Map
+1-626-3037902 (Phone)
+1-626-3032962 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye. The Company is the maker of lenses used worldwide in corrective or refractive surgery. It also makes lenses for use in surgery that treats cataracts. All of the lenses it makes are foldable, which permits the surgeon to insert them through a small incision during minimally invasive surgery. Refractive surgery corrects the types of visual disorders that glasses or contact lenses have traditionally treated. It refers to its lenses used in refractive surgery as implantable Collamer lenses (ICLs). The field of refractive surgery includes both lens-based procedures, using products like its ICL, and laser-based procedures like laser-assisted in-situ keratomileusis (LASIK). STAAR�s principal products are intraocular lens (IOLs) and ICLs used in ophthalmic surgery.

Officers and directors

Don M. Bailey Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Barry Caldwell President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Deborah Andrews Chief Financial Officer, Vice President
Age: 54
Bio & Compensation  - Reuters
Hans-Martin Blickensdoerfer President, Europe, Middle East, Africa, Latin America
Age: 46
Bio & Compensation  - Reuters
Donald Todd President, Asia Pacific
Age: 59
Bio & Compensation  - Reuters
Hideo Watanabe President, STAAR Japan
Age: 60
Bio & Compensation  - Reuters
Paul Hambrick Vice President - Global Operations
Age: 50
Bio & Compensation  - Reuters
Philippe Subrin Vice President - Switzerland Operations
Age: 48
Bio & Compensation  - Reuters
Samuel J. Gesten Vice President, General Counsel, Corporate Compliance Officer and Secretary
Age: 50
Bio & Compensation  - Reuters
Robin Hughes Vice President - Research and Development, Regulatory and Quality
Age: 48
Bio & Compensation  - Reuters